No Data
No Data
H.C. Wainwright Maintains Processa Pharmaceuticals(PCSA.US) With Buy Rating, Maintains Target Price $8
H.C. Wainwright analyst Ram Selvaraju maintains $Processa Pharmaceuticals(PCSA.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate o
Express News | Processa Pharmaceuticals Shares Are Trading Higher After the Company Announced Efficacy Results From a Preliminary Evaluation of Its Phase 1b Dose-escalating Trial With NGC-Cap in Gastrointestinal Cancer
Express News | Processa Pharmaceuticals - Preliminary Analysis of Efficacy Data Showed Early Evidence of Anti-Tumor Activity of Capecitabine Combined With Pcs6422
Express News | Processa Pharmaceuticals Inc - Eight of 12 Evaluable Patients (66.7%) Had Progression-Free Survival (Pfs) Ranging From 5 to 11 Months
Express News | Processa Pharmaceuticals Inc - at Highest Ngc-Cap Dose, All Three Evaluable Patients Had Pfs With Two Partial Responses (Pr) and One Stable Disease
Express News | Processa Pharmaceuticals Announces Positive Efficacy Results From Preliminary Evaluation of Phase 1B Dose-Escalating Trial With Ngc-Cap in Gastrointestinal Cancer
No Data